IPP Bureau
Genomic data opened to researchers
By IPP Bureau - March 21, 2022
All of Us Research Program releases genomic data to researchers, combined with participant-generated data collected on Vibrent Health’s research platform
Biological Dynamics study demonstrates detection of early-stage cancers
By IPP Bureau - March 21, 2022
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
physIQ and CellCarta collaborate to personalise vaccine development
By IPP Bureau - March 21, 2022
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Zydus receives PAS approval for Mycophenolate Mofetil
By IPP Bureau - March 21, 2022
The drug is indicated for use in combination with other drugs
Mylab to open new facility in Vishakhapatnam
By IPP Bureau - March 21, 2022
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
Hetero gets CDSCO approval to manufacture and sell Sputnik Light in India
By IPP Bureau - March 21, 2022
Sputnik Light is the first component of Sputnik V
Augnito.ai offers new features to woo doctors to its platform
By IPP Bureau - March 21, 2022
Augnito in association with Japanese company Fujifilm enables voice recognition within their radiology information system platform
Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets
By IPP Bureau - March 21, 2022
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Wockhardt and Serum Life Sciences UK partner to manufacture multiple vaccines in UK
By IPP Bureau - March 21, 2022
The facility will produce 150 million vaccine doses per year
ABclonal Technology joins YCharOS advisory committee to tackle reproducibility crisis in biomedical research
By IPP Bureau - March 21, 2022
Inconsistent antibody performance is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research
RNAGene and PharmAbcine to develop novel mRNA therapeutics
By IPP Bureau - March 21, 2022
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
Lonza signs manufacturing agreement with Oasmia Pharmaceutical
By IPP Bureau - March 21, 2022
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Govt to deploy Truenat platform for TB screening across India
By IPP Bureau - March 19, 2022
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Jubilant Pharmova arm receives ANDA approval for psychoneurosis drug
By IPP Bureau - March 19, 2022
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
Akston Biosciences and Biolexis partner to develop second-gen COVID-19 vaccine
By IPP Bureau - March 19, 2022
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
